Role of newer medications for bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 16, Issue 2 SUPPL. 1, 1996, Pages

  Bowden, Charles L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LITHIUM; NEFAZODONE; RISPERIDONE; VALPROATE SEMISODIUM; VENLAFAXINE;

BIPOLAR DEPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MOOD; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY;

EID: 0030001628     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199604001-00006     Document Type: Review

References (65)

1. Goldberg JF, Harrow M, Grossman LS. Recurrent affective syndromes in bipolar and unipolar mood disorders at follow-up. Br J Psychiatry 1995;166:382-5.
2. Stokes PE, Shamoian CA, Stoll PM, Patton MJ. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971;1:1319-25.
3. Sachs GS, Lafer B, Truman CJ, Noeth M, Thibault AB. Lithium monotherapy: miracle, myth and misunderstanding. Psychiatr Ann 1994;24:299-306.
4. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD, for the Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-24.
5. Bochetta A, Bernardi F, Pedditzi M. Thyroid abnormalities during lithium treatment. Acta Psychiatr Scand 1991;83:193-8.
6. Gitlin M. Lithium-induced renal insufficiency. J Clin Psychopharmacol 1993;13:276-9.
7. Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. Arch Gen Psychiatry 1979;36:866-9.
8. Papatheodorou G, Kutcher SP, Katic M, Szalai JP. The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial. J Clin Psychopharmacol 1995;15:110-6.
9. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990.
10. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RMA. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994;31:281-94.
11. Lambert PA, Cavaz G, Borselli S, Carrel S. Action neuropsychotrope d'un nouvel anti-epileptique: le depamide. Ann Med Psychol (Paris) 1966;1:707-10.
12. Takezaki H, Hanaoka M. The use of carbamazepine (Tegretol) in the control of manic depressive psychosis and other manic-depressive states. Psychiatr Neurol Jpn 1971;13:173-83.
13. Janicak PG, Pandey G, Sharma RP, Peterson J, Leach A, Davis JM. Verapamil versus placebo for acute mania. Preliminary results from a double-blind study. 148th Annual Meeting of the American Psychiatric Association. Miami, FL, 1995.
14. Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri T, Holtman HM, DePriest M. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders. J Clin Psychiatry 1995;56:466-70.
15. Bowden CL, Calabrese JR, Wallin BA. Who enters therapeutic trials? Illness characteristics of patients in clinical drug studies of mania. Psychopharmacol Bull 1995;31:103-9.
16. West SA, Strakowski SM, Sax K. The phenomenology and comorbidity of adolescents hospitalized for the treatment of acute mania [abstract]. 148th Annual Meeting of the American Psychiatric Association. Miami, FL, 1995.
17. Geller B, Fox LW, Clark KA. Rate and predictors of prepubertal bipolarity during follow-up of 6 to 12 year-old depressed children. J Am Acad Child Adolesc Psychiatry 1994;33:461-8.
18. Gelenberg AJ, Kane JN, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorders. N Engl J Med 1989;321:1489-93.
19. Secunda SK, Katz MM, Swann AC, Koslow SH, Maas JW, Chuang S, Croughan J. Mania: diagnosis, state measurement and prediction of treatment response. J Affect Disord 1985;8:113-21.
20. Leon AC, Shear MK, Portera L, Klerman GL. Effect size as a measure of symptom-specific drug change in clinical trials. Psychopharmacol Bull 1993;29:163-7.
21. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984;41:1096-104.
22. Lerer B, Moore N, Meyendorff E, Cho S-R, Gershon S. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987;48:89-93.
23. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48:62-A
24. Balfour JA, Bryson HM. Valproic acid: a review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs 1994;2:144-73.
25. Dubovsky S, Franks RD, Allen S, Murphy J. Calcium antagonists in mania: a double blind study of verapamil. Psychiatry Res 1986;18:309-20.
26. Giannini AJ, House WL, Loiselle RH. Antimanic effects of verapamil [abstract]. Am J Psychiatry 1984;141:1602-3.
27. Barton BM, Gitlin MJ. Verapamil in treatment-resistant mania: an open trial. J Clin Psychopharmacol 1987;7:101-3.
28. Wilder BJ, Karas BJ, Penry JK, Asconape J. Gastrointestinal tolerance of divalproex sodium. Neurology 1983;33:808-11.
29. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990;147:431-4.
30. Bowden CL. Treatment of bipolar disorder. In: Schatzberg A, Nemeroff C, eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, Inc., 1995.
31. Mitchell P. Valproate for rapid-cycling unipolar affective disorder. J Nerv Ment Dis 1991;179:503-4.
32. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled, cross-over study. Neurology 1994;44:647-51.
33. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990;35:248-50.
34. Herridge PL, Pope HG. Treatment of bulimia and rapid cycling bipolar disorder with sodium valproate: a case report. J Clin Psychopharmacol 1985;5:229-30.
35. Calabrese JR, Bowden C, Woyshville MJ. Lithium and anticonvulsants in bipolar disorder. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1994:1099-111.
36. Levy RH, Penry JK, eds. Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity. New York: Raven Press, 1991.
37. Gomez-Bellver MJ, Garcia Sanchez MJ, Alonso Gonzalez AC, Santos Buelga D, Dominguez-Gil A. Plasma protein binding kinetics of valproic acid over a borad dosage range: therapeutic implications. J Clin Pharm Ther 1993;18:191-7.
38. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic response to carbamazepine. Psychiatry Res 1987;21:71-83.
39. Post RM, Leverich GS, Rosoff AS, Altshuler LL. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990;10:318-27.
40. Frankenburg FR, Tohen M, Cohen BM, Lipinski JF. Long term response to carbamazepine: a retrospective study. J Clin Psychopharmacol 1988;8:130-2.
41. Post RM, Ketter TA, Denicoff K. The place of anticonvulsant therapy compared with lithium in the management of manic states. Psychopharmacology (Berl), submitted for publication.
42. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994;12[suppl]:1-36.
43. Cloyd J. Antiepileptic drug interactions: mechanisms and clinical implications. In: Pellock J, ed. Antiepileptic drugs: drug interactions and adverse effects. Deerfield, IL: Discovery International, 1995:42-51.
44. Denicoff KD, Smith-Jackson E, Disney E, Leverich GS, Post RM. Outcome in bipolar patients randomized to lithium or carbamazepine prophylaxis and crossed over in year two [abstract]. First International Conference on Bipolar Disorder. Pittsburgh, PA, 1994.
45. McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, O'Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-4.
46. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-80.
47. Dwight MM, Keck PE, Stanton SP, Strakowski SM, McElroy SL. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder [letter]. Lancet 1994;344:554-5.
48. Owens DG. Extrapyramidal side effects and tolerability of risperi-done: a review. J Clin Psychiatry 1994;55:29-35.
49. Schotte A, Janssen PF, Megens AA, Leysen JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 1993;631:191-202.
50. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1995;49:257-72.
51. Calabrese J. Lamotrigine in treatment refractory manic depression [abstr]. 2nd International Conference on New Directions in Affective Disorders. Jerusalem, Israel, 1995.
52. Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. J Clin Psychopharmacol 1992;12:276-81.
53. Kramlinger KG, Post RM. Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand 1989;79:378-85.
54. Citrome L. The use of lithium, carbamazepine, and valproic acid in a state operated psychiatric hospital. J Pharm Technol 1995;11:55-9.
55. Goldstein MJ, Miklowitz DJ. Family intervention for persons with bipolar disorder. New Dir Ment Health Serv 1994;62:23-35.
56. Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 1994;331:591-8.
57. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-22.
58. Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990;51:450-5.
59. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman BA. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152:1130-8.
60. Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? J Clin Psychiatry 1992;53:443-6.
61. Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;327:327-33.
62. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan S. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-23.
63. Judd L. Effect of lithium on mood, cognition and personality function in normal subjects. Arch Gen Psychiatry 1979;36:860-5.
64. Vestergaard P, Poulstrup I, Schou M. Prospective studies in a lithium cohort. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988;78:434-41.
65. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment of bipolar disorder. Arch Gen Psychiatry 1991;48:1082-8.